{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sheward DJ"],"funding":["NIAID NIH HHS"],"pagination":["101577"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11228396"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(6)"],"pubmed_abstract":["Descendants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant now account for almost all SARS-CoV-2 infections. The Omicron variant and its sublineages have spike glycoproteins that are highly diverged from the pandemic founder and first-generation vaccine strain, resulting in significant evasion from monoclonal antibody therapeutics and vaccines. Understanding how commonly elicited antibodies can broaden to cross-neutralize escape variants is crucial. We isolate IGHV3-53, using \"public\" monoclonal antibodies (mAbs) from an individual 7 months post infection with the ancestral virus and identify antibodies that exhibit potent and broad cross-neutralization, extending to the BA.1, BA.2, and BA.4/BA.5 sublineages of Omicron. Deep mutational scanning reveals "],"journal":["Cell reports. Medicine"],"pubmed_title":["Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies."],"pmcid":["PMC11228396"],"funding_grant_id":["R01 AI141707"],"pubmed_authors":["Kim C","Peacock TP","Dopico XC","Greaney AJ","Lee J","Sheward DJ","Corcoran M","Hallberg BM","Kim S","Murrell B","Dosenovic P","Bloom JD","Das H","Pushparaj P","Albert J","Hyllner E","Dyrdak R","Hanke L","McInerney GM","Karlsson Hedestam GB"],"additional_accession":[]},"is_claimable":false,"name":"Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies.","description":"Descendants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant now account for almost all SARS-CoV-2 infections. The Omicron variant and its sublineages have spike glycoproteins that are highly diverged from the pandemic founder and first-generation vaccine strain, resulting in significant evasion from monoclonal antibody therapeutics and vaccines. Understanding how commonly elicited antibodies can broaden to cross-neutralize escape variants is crucial. We isolate IGHV3-53, using \"public\" monoclonal antibodies (mAbs) from an individual 7 months post infection with the ancestral virus and identify antibodies that exhibit potent and broad cross-neutralization, extending to the BA.1, BA.2, and BA.4/BA.5 sublineages of Omicron. Deep mutational scanning reveals ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2026-06-01T07:37:28.23Z","creation":"2025-04-04T11:25:08.643Z"},"accession":"S-EPMC11228396","cross_references":{"pubmed":["38761799"],"doi":["10.1016/j.xcrm.2024.101577"]}}